What Tranquil Treats: Main Uses and Benefits

Tranquil (Clobazam) is a therapeutic agent used primarily in two distinct domains, supporting the management of significant neurological and emotional symptom clusters. Its clinical application is relevant for easing symptoms related to heightened physiological activity, which contributes to easing the overall symptom load.

Clinical Focus and Therapeutic Benefit

This medication is commonly used to help with Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy, and for the short-term relief of pronounced symptoms associated with severe anxiety states. In the management of LGS, Clobazam is typically used in conjunction with other medications to control seizures.

In seizure disorders, Tranquil is an essential adjunctive treatment applied when multiple primary anticonvulsant agents have failed to achieve adequate control. It plays a role in managing the frequency and intensity of various severe convulsive and non-convulsive events, such as atonic or tonic seizures, which helps maintain a sense of stability when symptoms are more noticeable. For patients with severe anxiety, the medication is relevant for easing symptom clusters that are overwhelming or difficult to tolerate.

“The therapy is relevant for easing symptoms during difficult episodes, and may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Heightened Symptoms

Property	Description
Primary Domain	Refractory Seizure Syndromes (e.g., LGS)
Secondary Domain	Severe Anxiety States
Target Symptoms	Convulsive events, emotional tension, psychological distress
Key Benefit	Contributes to easing the overall symptom load

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Tranquil (Clobazam)

The eligibility for Tranquil (Clobazam) is strictly defined by official regulatory documents based on age, physiological status, and pre-existing conditions. This section details the specific population-use rules as stated in approved regulatory labeling.

---

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated in patients with known hypersensitivity to Clobazam or other benzodiazepines. Contraindications also apply to individuals with Myasthenia Gravis, severe respiratory insufficiency, Sleep Apnoea Syndrome, severe hepatic insufficiency (Child-Pugh Class C), and a history of drug or alcohol dependence.

---

Age- and Condition-Based Restrictions

• Established Use: Adults and children ge 2 years of age are eligible for the approved indication. Use in children <2 years is not established for this indication.
• Older Adults ( ge 65 years): Eligible, but require a lower initial starting dose and slower titration.
• Hepatic Function: Severe liver disease is a contraindication. Patients with mild or moderate impairment are eligible but must use a reduced starting dose.
• Pregnancy and Lactation: Use is contraindicated during the first trimester of pregnancy and is generally contraindicated for women who are breastfeeding. Use during pregnancy is otherwise permitted only if the potential benefit justifies the potential risk to the fetus.
• Metabolic Status: Patients known to be CYP2C19 Poor Metabolizers require special caution and a lower starting dose.

Interactions with other medicines and products

Tranquil (Clobazam) interacts with other substances primarily through two documented mechanisms: enhancing the effects of CNS depressants and altering hepatic metabolic pathways. All information presented is strictly aligned with regulatory labeling.

Documented Pharmacodynamic and Substance Interactions

Co-administration with Opioids and other Central Nervous System (CNS) depressants is officially documented to carry a heightened risk of profound sedation, respiratory depression, and potential for coma. This effect is classified as pharmacodynamic reinforcement. Consumption of alcohol (ethanol) increases Clobazam blood concentrations by approximately 50%, which further potentiates the risk of CNS depression. Additionally, the regulatory profile identifies an interaction with Cannabidiol (CBD), which increases the likelihood of adverse reactions and raises the exposure of Clobazam's active metabolite, N-desmethylclobazam.

Metabolic and Exposure-Altering Interactions

The drug is classified as a weak inhibitor of Cytochrome P450 2D6 (CYP2D6). This pharmacokinetic interaction may increase the systemic exposure of other medicines that are substrates for CYP2D6. Conversely, strong or moderate inhibitors of CYP2C19 are documented to increase the plasma levels of Clobazam's primary active metabolite, N-desmethylclobazam. Specific population considerations are documented for individuals classified as CYP2C19 Poor Metabolizers, who are expected to have inherently increased levels of N-desmethylclobazam due to reduced clearance. No mandatory timing-based separation rules are documented in the official labeling.

How Tranquil Works

Tranquil operates primarily as a positive allosteric modulator of the GABA-A receptor complex within the central nervous system (CNS). By binding to a specific site distinct from the GABA neurotransmitter binding site, the drug increases the GABA-A receptor's affinity for its natural ligand, thereby amplifying the inherent inhibitory signals.

This molecular interaction initiates a cellular cascade: the amplified GABA signal results in a sustained opening of the receptor's integral chloride ion ( Cl^-) channel. The consequent influx of Cl^- causes the neuronal membrane to hyperpolarize, making the nerve cell significantly less excitable. This dampening of neural activity reduces the speed and frequency of signal transmission throughout the CNS.

The resulting physiological modulation is a widespread suppression of neural firing rate. By acting on the regulatory systems that govern CNS excitability and overall muscle tone, the mechanism produces observable physiological states, specifically generalized sedation and centrally mediated skeletal muscle relaxation.

Tranquil, which contains the active ingredient Clobazam, is administered exclusively via the oral route and is available in multiple pharmaceutical forms, including the standard tablet, an oral liquid suspension, and an oral soluble film. The general usage principle involves initiating therapy with a low dose followed by slow adjustment.

For adults over 30 kg body weight, the typical starting dose is 10 mg per day. The total daily dose is then increased, or titrated, in small increments, but this escalation must occur no more rapidly than weekly to allow the medicine to stabilize in the body, with a labeled maximum daily dose of 40 mg. The medicine can be administered with or without food.

Administration frequency is determined by the dose amount. Total daily doses of 5 mg or less may be taken once daily, while doses greater than 5 mg must be administered in two divided doses (twice daily). For proper intake of the oral suspension, the product must be shaken well before measurement, and the oral film must be placed on the tongue and dissolved without being chewed or swallowed with liquid.

For specific patient groups, the initiation regimen is adjusted. Older adults and those with mild to moderate hepatic impairment must begin with a lower starting dose of 5 mg per day, and their subsequent dose increases must proceed at half the usual rate. When treatment is concluded, the medicine cannot be stopped suddenly; instead, the total daily dose must be gradually reduced in a controlled process, typically by 5 to 10 mg per day on a weekly basis.

Research Evidence / Overview of Studies for Tranquil

Research for Tranquil (Clobazam) has evaluated its use in two main contexts: as an adjunctive treatment (add-on) for Lennox-Gastaut Syndrome (LGS), a rare form of epilepsy, and in studies exploring conditions with periods of heightened symptoms, such as anxiety. This overview describes the research structure without making any claims about clinical outcomes or providing medical advice.

---

Evidence for use in Lennox-Gastaut Syndrome (LGS)

The primary and most rigorous research exploring Tranquil has focused on LGS, a condition characterized by fluctuating or episodic manifestations of various seizure types.

These studies, classified as Randomized Controlled Trials (RCTs), followed double-blind designs and was studied for its use as an adjunctive therapy. Researchers examined outcomes such as the percentage change in the mean weekly frequency of drop seizures and recorded the proportion of patients whose seizure frequency change met a pre-defined threshold.

Findings from these controlled studies described the data patterns observed in the study populations, which included children and adults. The evidence includes data concerning seizure patterns, particularly regarding drop seizures. The evidence base for Tranquil, while classified as the highest level for the core LGS indication, primarily focuses on add-on use, meaning limited information for long-term outcomes exists regarding its use as a single treatment (monotherapy).

Evidence for Anxiety and Broader Epilepsy Use

Research has also explored Clobazam in studies investigating other contexts, including conditions associated with acute or disruptive episodes, such as certain anxiety states, and in forms of drug-resistant epilepsy outside of LGS. Evidence quality varies across studies for these research areas.

For anxiety, the available evidence structure includes older, historical double-blind studies. For broader refractory epilepsy, the research relies mostly on retrospective observational studies. Outcomes monitored included the long-term retention rate on the research medicine over defined follow-up periods. Research for anxiety and broader refractory epilepsy often relies on retrospective data, where certainty remains low compared to the core LGS RCTs.

---

Evidence Gaps and Areas of Ongoing Research

Data for certain groups remain insufficient, particularly in specific comorbidity groups or older populations not included in the main controlled trials. These research limitations highlight what is known and what is still uncertain, emphasizing that study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Clobazam: MedlinePlus Drug Information
2. Adjunctive Clobazam in Patients With Lennox-Gastaut Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

Common questions about Tranquil (FAQ)

Q: What is the main purpose of Tranquil?

A: Regulatory documents state that Tranquil is used to manage certain symptoms associated with a specific medical condition. Studies and official information indicate that it works in the central nervous system to help manage the targeted symptoms. This information is based on the drug's official regulatory labeling.

Q: How long does it take for Tranquil to start working?

A: Official product information indicates that the time it takes for Tranquil's effects to become noticeable can vary among individuals. Regulatory documents emphasize the importance of following the prescribed treatment schedule. Full effectiveness may require consistent administration over time.

Q: Can Tranquil be taken with food?

A: According to the official product information, Tranquil may be taken with or without food. Patients are encouraged to follow any specific instructions provided by their healthcare professional. Consistency in administration, as directed, is generally part of the prescribed regimen.

Q: What should I do if I miss a dose of Tranquil?

A: Regulatory documents outline the standard protocol for a missed dose, which typically involves taking the dose when remembered unless the next dose is due soon. It is specifically advised against taking two doses at once to compensate for a missed dose, as detailed in the safety information. Detailed instructions are provided in the product information.

Q: Is Tranquil habit-forming or addictive?

A: Official information indicates that Tranquil has a low risk of dependency when used as prescribed. Official sources provide documentation on the dependency risk associated with its use, which is considered low when taken as prescribed. The medicine belongs to a class documented in regulatory reviews.

Q: Can Tranquil affect my ability to drive or operate machinery?

A: According to the official product information, Tranquil can cause side effects such as drowsiness or dizziness in some individuals. Patients are advised to exercise caution and avoid potentially hazardous activities like driving or operating machinery until they are aware of the medicine’s specific effect on their abilities.

Q: How should I store Tranquil?

A: Regulatory documents recommend that Tranquil should be stored at room temperature, away from moisture and heat. It must be kept out of the reach of children and pets. Following the recommended storage guidelines helps maintain the quality and integrity of the medicine.

Q: Is it safe to suddenly stop taking Tranquil?

A: Official product information advises against the sudden discontinuation of Tranquil. Abruptly stopping the medicine may lead to withdrawal symptoms or the return of targeted symptoms. Official guidance emphasizes that any modification to the prescribed treatment plan, including discontinuation, must be decided by a healthcare professional.

Storage and Disposal Requirements

Official regulatory documents define strict conditions for storing and disposing of Tranquil (Clobazam) to maintain stability and prevent misuse.

Storage Conditions

Requirement	Details
Temperature and Environment	Store tablets and oral films at room temperature, away from heat, moisture, and direct light. Do not freeze.
Container Integrity	The medicine must be kept in a closed container. For the oral suspension, the cap must be securely replaced after each opening.
Child Safety	The medication must be kept out of the reach of children. As a controlled substance, it should be stored securely to protect it from theft or misuse.

Disposal and Stability

For the oral suspension form, any unused liquid must be discarded 90 days after the bottle is opened for the first time. Outdated or unneeded medicine must not be kept. Disposal of any unused product must be done in accordance with local and national regulations, often requiring consultation with a healthcare professional to ensure proper handling of pharmaceutical waste.